title: Use of synthesis inhibitors in defining a role for biogenic amines during imipramine treatment in depressed patients.
abstract: Endogenously depressed patients who showed an antidepressant response to the tricyclic drug imipramine continued to show sustained well being after alpha-MPT was added whereas depression returned when small doses of PCPA were added for brief periods. In one patient the antidepressant response to imipramine occurred after pre- and continued treatment with alpha-MPT. Urinary excretion levels of MHPG in one of the patients studied longitudinally did not correspond to the direction of clinical affective state but did reflect anticipated changes during alpha-MPT treatment. Implications are that serotonergic mechanisms are likely involved in the anti-depressant effects of imipramine in man.
mesh_terms: D015098:3-Methoxy-4-hydroxyphenylethanol / Q000652:urine; D000328:Adult; D000963:Antimetabolites / Q000494:pharmacology*; D001679:Biogenic Amines / Q000378:metabolism*; D002986:Clinical Trials as Topic; D003863:Depression / Q000188:drug therapy*; D005260:Female; D010134:Fenclonine / Q000494:pharmacology; D006801:Humans; D007099:Imipramine / Q000037:antagonists & inhibitors / Q000627:therapeutic use*; D008297:Male; D008781:Methyltyrosines / Q000494:pharmacology; D008875:Middle Aged; D009638:Norepinephrine / Q000378:metabolism; D011569:Psychiatric Status Rating Scales; D013997:Time Factors
chemical_list: D000963:Antimetabolites; D001679:Biogenic Amines; D008781:Methyltyrosines; D015098:3-Methoxy-4-hydroxyphenylethanol; D007099:Imipramine; D010134:Fenclonine; D009638:Norepinephrine